Please assess the completion status of the following clinical trial:

Trial Title: BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. pathologically confirmed diagnosis of stage IIIB or stage IV adenocarcinoma of the Lung~2. EGFR(Epidermal Growth Factor Receptor) mutation detected by central laboratory analysis of tumor biopsy material~3. Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST)1.1~4. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.~5. Age\>=18 years~6. life expectancy of at least three months~7. Written informed consent that is consistent with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines.~Exclusion criteria:~1. Prior chemotherapy for relapsed and/or metastatic NSCLC.~2. Prior treatment with EGFR targeting small molecules or antibodies.~3. Radiotherapy or surgery(other than biopsy) within 4 weeks prior to randomization~4. Active brain metastases~5. Any other current malignancy or malignancy diagnosed within the past 5 years~6. Known pre-existing interstitial lung disease~7. Significant or recent acute gastrointestinal disorders with diarrhoea as a a major symptoms.~8. History or presence of clinically relevant cardiovascular abnormalities~9. Cardiac left ventricular function with resting ejection fraction of less than 50%.~10. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.~11. Absolute neutrophil count(ANC)\<1500/mm3~12. Platelet count\<100,000/mm3~13. Creatinine clearance\<60ml/min or serum creatinine\>1.5 times Upper Limit of Normal (ULN).~14. Bilirubin\>1.5 times ULN~15. Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) \> 3 times ULN~16. Women of childbearing potential, or men who are able to father a child, unwilling to use a medically acceptable method of contraception during the trial~17. Pregnancy of breast-feeding~18. Patients unable to comply with the protocol~19. Active hepatitis B infection, active hepatitis C infection or known HIV(Human Immunodeficiency Virus) carrier.~20. Known or suspected active drug or alcohol abuse.~21. requirement for treatment with any of the prohibited concomitant medications listed in section 4.2.2~22. Any contraindications for therapy with gemcitabine/cisplatin~23. Known hypersensitivity to BIBW2992 or the excipient of any of the trial drugs~24. Use of any investigational drug within 4 weeks of randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A BIBW 2992 (Type: EXPERIMENTAL): Patients receive a tablet of BIBW 2992 daily until progression or unacceptable toxicity
- Arm B Chemotherapy (Type: ACTIVE_COMPARATOR): Patients receive Gemcitabine and Cisplatin, maximum is 6 courses

Based on this trial design, predict the completion outcome and termination type (if applicable).